H2N2V1, Istex, Corpus, bibRecord, 001421

Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic

Identifieur interne : 001421 ( Istex/Corpus ); précédent : 001420; suivant : 001422

Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic

Auteurs : Penelope Ward ; Ian Small ; James Smith ; Pia Suter ; Regina Dutkowski

Source :

Journal of Antimicrobial Chemotherapy [ 0305-7453 ] ; 2005.

RBID : ISTEX:922F9D3E26EBD54DF6D00A45F3E4732514BE6241

English descriptors

Teeft :
- Adverse events, American journal, Animal models, Antimicrobial, Antimicrobial agents, Antimicrobial chemotherapy, Antiviral, Antiviral research, Avian, Biological properties, Carboxylate, Chemoprophylaxis, Chemotherapy, Clinical studies, Dos, Dosing, Drug resistance, England journal, Febrile illness, Hayden, Hong kong, Infection, Infectious diseases, Inhibitor, Mutation, Neuraminidase, Neuraminidase inhibitors, Oseltamivir, Oseltamivir carboxylate, Oseltamivir phosphate, Oseltamivir treatment, Outbreak, Pandemic, Pandemic situation, Pandemic strain, Placebo, Potential risk, Pregnant women, Prophylaxis, Replication, Resistant virus, Resistant viruses, Respiratory disease, Roche, Safety data, Stockpile, Subtypes, Vaccine, Viral, Viral replication, Virology, Virus, Virus infection, Virus transmission, Welliver, Zanamivir.

Abstract

Recent cross species transmission of avian influenza has highlighted the threat of pandemic influenza. Oseltamivir (Tamiflu®) has been shown to be effective in the treatment and prevention of epidemic influenza infection in adults, adolescents and children (≥ 1 year). Although oseltamivir has not been approved for prophylactic use in children, it has been shown to be effective. Oseltamivir is also active against avian influenza virus strains. Evidence suggests that lower doses or shorter durations of treatment/chemoprophylaxis other than those approved may not be effective and may contribute to emergence of viral resistance. Safety data from dose ranging studies show that 5 day courses of 150 mg twice daily for treatment and 6 week courses of 75 mg twice daily for prophylaxis were as well tolerated as the approved dose regimens. The use of oseltamivir in a pandemic is influenced by the goals of the pandemic plan developed by the responsible Government and Health Authority. To optimize use of antiviral medications, processes will be needed to collect, collate and report outcome data from treated patients and/or from use for chemoprophylaxis of pandemic influenza during the first-wave outbreaks. If oseltamivir is included in a national or regional pandemic plan, stockpiling of the material, either in the form of capsules or the bulk active pharmaceutical ingredient will be necessary. In the absence of a stockpile, there is no guarantee that an adequate supply of oseltamivir will be available.

Url:

https://api.istex.fr/ark:/67375/HXZ-Z7QWKL7C-1/fulltext.pdf

DOI: 10.1093/jac/dki018

Links to Exploration step

ISTEX:922F9D3E26EBD54DF6D00A45F3E4732514BE6241

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic</title>
<author><name sortKey="Ward, Penelope" sort="Ward, Penelope" uniqKey="Ward P" first="Penelope" last="Ward">Penelope Ward</name>
<affiliation><mods:affiliation>Roche Products Ltd, Welwyn Garden City, Herts, UK;</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>*Corresponding author. Tel: +44-1707-362843; Fax: +44-1707-365887; Email: penelope.ward@roche.com</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Small, Ian" sort="Small, Ian" uniqKey="Small I" first="Ian" last="Small">Ian Small</name>
<affiliation><mods:affiliation>Roche Products Ltd, Welwyn Garden City, Herts, UK;</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Smith, James" sort="Smith, James" uniqKey="Smith J" first="James" last="Smith">James Smith</name>
<affiliation><mods:affiliation>F. Hoffmann-La Roche, Basle, Switzerland;</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Suter, Pia" sort="Suter, Pia" uniqKey="Suter P" first="Pia" last="Suter">Pia Suter</name>
<affiliation><mods:affiliation>F. Hoffmann-La Roche, Basle, Switzerland;</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Dutkowski, Regina" sort="Dutkowski, Regina" uniqKey="Dutkowski R" first="Regina" last="Dutkowski">Regina Dutkowski</name>
<affiliation><mods:affiliation>F. Hoffmann-La Roche Inc, Nutley, NJ, USA</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:922F9D3E26EBD54DF6D00A45F3E4732514BE6241</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1093/jac/dki018</idno>
<idno type="url">https://api.istex.fr/ark:/67375/HXZ-Z7QWKL7C-1/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001421</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001421</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Oseltamivir (Tamiflu<hi rend="superscript">®</hi>
) and its potential for use in the event of an influenza pandemic</title>
<author><name sortKey="Ward, Penelope" sort="Ward, Penelope" uniqKey="Ward P" first="Penelope" last="Ward">Penelope Ward</name>
<affiliation><mods:affiliation>Roche Products Ltd, Welwyn Garden City, Herts, UK;</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>*Corresponding author. Tel: +44-1707-362843; Fax: +44-1707-365887; Email: penelope.ward@roche.com</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Small, Ian" sort="Small, Ian" uniqKey="Small I" first="Ian" last="Small">Ian Small</name>
<affiliation><mods:affiliation>Roche Products Ltd, Welwyn Garden City, Herts, UK;</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Smith, James" sort="Smith, James" uniqKey="Smith J" first="James" last="Smith">James Smith</name>
<affiliation><mods:affiliation>F. Hoffmann-La Roche, Basle, Switzerland;</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Suter, Pia" sort="Suter, Pia" uniqKey="Suter P" first="Pia" last="Suter">Pia Suter</name>
<affiliation><mods:affiliation>F. Hoffmann-La Roche, Basle, Switzerland;</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Dutkowski, Regina" sort="Dutkowski, Regina" uniqKey="Dutkowski R" first="Regina" last="Dutkowski">Regina Dutkowski</name>
<affiliation><mods:affiliation>F. Hoffmann-La Roche Inc, Nutley, NJ, USA</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Journal of Antimicrobial Chemotherapy</title>
<title level="j" type="issue">Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic</title>
<title level="j" type="abbrev">J. Antimicrob. Chemother.</title>
<idno type="ISSN">0305-7453</idno>
<idno type="eISSN">1460-2091</idno>
<imprint><publisher>Oxford University Press</publisher>
<date when="2005-02">2005</date>
<biblScope unit="vol">55</biblScope>
<biblScope unit="issue">suppl_1</biblScope>
<biblScope unit="page" from="i5">i5</biblScope>
<biblScope unit="page" to="i21">i21</biblScope>
</imprint>
<idno type="ISSN">0305-7453</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0305-7453</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse events</term>
<term>American journal</term>
<term>Animal models</term>
<term>Antimicrobial</term>
<term>Antimicrobial agents</term>
<term>Antimicrobial chemotherapy</term>
<term>Antiviral</term>
<term>Antiviral research</term>
<term>Avian</term>
<term>Biological properties</term>
<term>Carboxylate</term>
<term>Chemoprophylaxis</term>
<term>Chemotherapy</term>
<term>Clinical studies</term>
<term>Dos</term>
<term>Dosing</term>
<term>Drug resistance</term>
<term>England journal</term>
<term>Febrile illness</term>
<term>Hayden</term>
<term>Hong kong</term>
<term>Infection</term>
<term>Infectious diseases</term>
<term>Inhibitor</term>
<term>Mutation</term>
<term>Neuraminidase</term>
<term>Neuraminidase inhibitors</term>
<term>Oseltamivir</term>
<term>Oseltamivir carboxylate</term>
<term>Oseltamivir phosphate</term>
<term>Oseltamivir treatment</term>
<term>Outbreak</term>
<term>Pandemic</term>
<term>Pandemic situation</term>
<term>Pandemic strain</term>
<term>Placebo</term>
<term>Potential risk</term>
<term>Pregnant women</term>
<term>Prophylaxis</term>
<term>Replication</term>
<term>Resistant virus</term>
<term>Resistant viruses</term>
<term>Respiratory disease</term>
<term>Roche</term>
<term>Safety data</term>
<term>Stockpile</term>
<term>Subtypes</term>
<term>Vaccine</term>
<term>Viral</term>
<term>Viral replication</term>
<term>Virology</term>
<term>Virus</term>
<term>Virus infection</term>
<term>Virus transmission</term>
<term>Welliver</term>
<term>Zanamivir</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent cross species transmission of avian influenza has highlighted the threat of pandemic influenza. Oseltamivir (Tamiflu®) has been shown to be effective in the treatment and prevention of epidemic influenza infection in adults, adolescents and children (≥ 1 year). Although oseltamivir has not been approved for prophylactic use in children, it has been shown to be effective. Oseltamivir is also active against avian influenza virus strains. Evidence suggests that lower doses or shorter durations of treatment/chemoprophylaxis other than those approved may not be effective and may contribute to emergence of viral resistance. Safety data from dose ranging studies show that 5 day courses of 150 mg twice daily for treatment and 6 week courses of 75 mg twice daily for prophylaxis were as well tolerated as the approved dose regimens. The use of oseltamivir in a pandemic is influenced by the goals of the pandemic plan developed by the responsible Government and Health Authority. To optimize use of antiviral medications, processes will be needed to collect, collate and report outcome data from treated patients and/or from use for chemoprophylaxis of pandemic influenza during the first-wave outbreaks. If oseltamivir is included in a national or regional pandemic plan, stockpiling of the material, either in the form of capsules or the bulk active pharmaceutical ingredient will be necessary. In the absence of a stockpile, there is no guarantee that an adequate supply of oseltamivir will be available.</div>
</front>
</TEI>
<istex><corpusName>oup</corpusName>
<keywords><teeft><json:string>oseltamivir</json:string>
<json:string>prophylaxis</json:string>
<json:string>neuraminidase</json:string>
<json:string>avian</json:string>
<json:string>antiviral</json:string>
<json:string>mutation</json:string>
<json:string>viral</json:string>
<json:string>pandemic</json:string>
<json:string>hayden</json:string>
<json:string>dosing</json:string>
<json:string>oseltamivir treatment</json:string>
<json:string>placebo</json:string>
<json:string>virology</json:string>
<json:string>outbreak</json:string>
<json:string>roche</json:string>
<json:string>pregnant women</json:string>
<json:string>chemotherapy</json:string>
<json:string>carboxylate</json:string>
<json:string>virus infection</json:string>
<json:string>welliver</json:string>
<json:string>antimicrobial</json:string>
<json:string>oseltamivir carboxylate</json:string>
<json:string>animal models</json:string>
<json:string>pandemic situation</json:string>
<json:string>zanamivir</json:string>
<json:string>subtypes</json:string>
<json:string>antiviral research</json:string>
<json:string>stockpile</json:string>
<json:string>resistant virus</json:string>
<json:string>infectious diseases</json:string>
<json:string>adverse events</json:string>
<json:string>chemoprophylaxis</json:string>
<json:string>virus</json:string>
<json:string>dos</json:string>
<json:string>replication</json:string>
<json:string>pandemic strain</json:string>
<json:string>oseltamivir phosphate</json:string>
<json:string>inhibitor</json:string>
<json:string>potential risk</json:string>
<json:string>hong kong</json:string>
<json:string>biological properties</json:string>
<json:string>england journal</json:string>
<json:string>antimicrobial agents</json:string>
<json:string>neuraminidase inhibitors</json:string>
<json:string>vaccine</json:string>
<json:string>antimicrobial chemotherapy</json:string>
<json:string>drug resistance</json:string>
<json:string>viral replication</json:string>
<json:string>american journal</json:string>
<json:string>respiratory disease</json:string>
<json:string>resistant viruses</json:string>
<json:string>febrile illness</json:string>
<json:string>virus transmission</json:string>
<json:string>safety data</json:string>
<json:string>clinical studies</json:string>
<json:string>infection</json:string>
<json:string>young adults</json:string>
<json:string>antiviral activity</json:string>
<json:string>registration studies</json:string>
<json:string>shorter durations</json:string>
<json:string>index cases</json:string>
<json:string>active metabolite</json:string>
<json:string>index case</json:string>
<json:string>symptomatic treatment</json:string>
<json:string>outbreak control</json:string>
<json:string>bone marrow transplantation</json:string>
<json:string>oseltamivir recipients</json:string>
<json:string>adequate supply</json:string>
<json:string>clinical trials</json:string>
<json:string>internal medicine</json:string>
<json:string>throat swabs</json:string>
<json:string>placebo group</json:string>
<json:string>clear evidence</json:string>
<json:string>potential pandemic strains</json:string>
<json:string>japanese children</json:string>
<json:string>further study</json:string>
<json:string>potential emergence</json:string>
<json:string>global neuraminidase inhibitor susceptibility network</json:string>
<json:string>death rate</json:string>
<json:string>active site</json:string>
<json:string>adverse event</json:string>
<json:string>antiviral prophylaxis</json:string>
<json:string>surveillance system</json:string>
<json:string>oseltamivir prophylaxis</json:string>
<json:string>cell surface</json:string>
<json:string>respiratory tract</json:string>
<json:string>virus life cycle</json:string>
<json:string>pneumonia</json:string>
<json:string>emergence</json:string>
<json:string>titre</json:string>
<json:string>cell surface receptors</json:string>
<json:string>several countries</json:string>
<json:string>overall conclusions</json:string>
<json:string>antibody response</json:string>
<json:string>poultry workers</json:string>
<json:string>expectant treatment</json:string>
<json:string>sialic acid</json:string>
<json:string>clinical symptoms</json:string>
<json:string>week courses</json:string>
<json:string>virus titres</json:string>
<json:string>paediatric contacts</json:string>
<json:string>simultaneous treatment</json:string>
<json:string>previous pandemic experience</json:string>
<json:string>nursing home populations</json:string>
<json:string>higher doses</json:string>
<json:string>paediatric cancer centre</json:string>
<json:string>health outcomes</json:string>
<json:string>immune response</json:string>
<json:string>placebo recipients</json:string>
<json:string>renal disease</json:string>
<json:string>symptomatic cases</json:string>
<json:string>clinical pattern</json:string>
<json:string>third trimesters</json:string>
<json:string>higher risk</json:string>
<json:string>serious complications</json:string>
<json:string>fetal toxicity</json:string>
<json:string>primary virus pneumonia</json:string>
<json:string>respiratory secretions</json:string>
<json:string>prospective study</json:string>
<json:string>viral titres</json:string>
<json:string>virus replication</json:string>
<json:string>dose regimens</json:string>
<json:string>daily dose group</json:string>
<json:string>pandemic plan</json:string>
<json:string>resistance mutations</json:string>
<json:string>studies show</json:string>
<json:string>healthy adults</json:string>
<json:string>recent publication</json:string>
<json:string>future pandemic</json:string>
<json:string>clinical trial</json:string>
<json:string>replicative ability</json:string>
<json:string>cell membrane</json:string>
<json:string>mathematical model</json:string>
<json:string>century pandemics</json:string>
<json:string>clinical samples</json:string>
<json:string>avian viruses</json:string>
<json:string>oral administration</json:string>
<json:string>chicken model</json:string>
<json:string>vast majority</json:string>
<json:string>antiviral medications</json:string>
<json:string>treatment studies</json:string>
<json:string>daily administration</json:string>
<json:string>oseltamivir therapy</json:string>
<json:string>rare cases</json:string>
<json:string>magistral formulation</json:string>
<json:string>powder formulations</json:string>
<json:string>epidemic modelling</json:string>
<json:string>clinical features</json:string>
<json:string>illness attack rate</json:string>
<json:string>nursing home outbreaks</json:string>
<json:string>eiss system</json:string>
<json:string>reference laboratories</json:string>
<json:string>surveillance systems</json:string>
<json:string>report outcome data</json:string>
<json:string>case welliver</json:string>
<json:string>case fever</json:string>
<json:string>other information</json:string>
<json:string>mathematical modelling</json:string>
<json:string>antiviral treatment</json:string>
<json:string>adamantane derivatives</json:string>
<json:string>young children</json:string>
<json:string>antigenic shift</json:string>
<json:string>clinical cases</json:string>
<json:string>roche research report</json:string>
<json:string>novel strain</json:string>
<json:string>disease journal</json:string>
<json:string>nursing home</json:string>
<json:string>relative increase</json:string>
<json:string>virus infections</json:string>
<json:string>royal society</json:string>
<json:string>disease management</json:string>
<json:string>avian virus</json:string>
</teeft>
</keywords>
<author><json:item><name>Penelope Ward</name>
<affiliations><json:string>Roche Products Ltd, Welwyn Garden City, Herts, UK;</json:string>
<json:string>*Corresponding author. Tel: +44-1707-362843; Fax: +44-1707-365887; Email: penelope.ward@roche.com</json:string>
</affiliations>
</json:item>
<json:item><name>Ian Small</name>
<affiliations><json:string>Roche Products Ltd, Welwyn Garden City, Herts, UK;</json:string>
</affiliations>
</json:item>
<json:item><name>James Smith</name>
<affiliations><json:string>F. Hoffmann-La Roche, Basle, Switzerland;</json:string>
</affiliations>
</json:item>
<json:item><name>Pia Suter</name>
<affiliations><json:string>F. Hoffmann-La Roche, Basle, Switzerland;</json:string>
</affiliations>
</json:item>
<json:item><name>Regina Dutkowski</name>
<affiliations><json:string>F. Hoffmann-La Roche Inc, Nutley, NJ, USA</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>treatment</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>therapy</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>neuraminidase inhibitors</value>
</json:item>
</subject>
<arkIstex>ark:/67375/HXZ-Z7QWKL7C-1</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>other</json:string>
</originalGenre>
<abstract>Recent cross species transmission of avian influenza has highlighted the threat of pandemic influenza. Oseltamivir (Tamiflu®) has been shown to be effective in the treatment and prevention of epidemic influenza infection in adults, adolescents and children (≥ 1 year). Although oseltamivir has not been approved for prophylactic use in children, it has been shown to be effective. Oseltamivir is also active against avian influenza virus strains. Evidence suggests that lower doses or shorter durations of treatment/chemoprophylaxis other than those approved may not be effective and may contribute to emergence of viral resistance. Safety data from dose ranging studies show that 5 day courses of 150 mg twice daily for treatment and 6 week courses of 75 mg twice daily for prophylaxis were as well tolerated as the approved dose regimens. The use of oseltamivir in a pandemic is influenced by the goals of the pandemic plan developed by the responsible Government and Health Authority. To optimize use of antiviral medications, processes will be needed to collect, collate and report outcome data from treated patients and/or from use for chemoprophylaxis of pandemic influenza during the first-wave outbreaks. If oseltamivir is included in a national or regional pandemic plan, stockpiling of the material, either in the form of capsules or the bulk active pharmaceutical ingredient will be necessary. In the absence of a stockpile, there is no guarantee that an adequate supply of oseltamivir will be available.</abstract>
<qualityIndicators><refBibsNative>false</refBibsNative>
<abstractWordCount>235</abstractWordCount>
<abstractCharCount>1515</abstractCharCount>
<keywordCount>3</keywordCount>
<score>7.82</score>
<pdfWordCount>14175</pdfWordCount>
<pdfCharCount>89181</pdfCharCount>
<pdfVersion>1.3</pdfVersion>
<pdfPageCount>17</pdfPageCount>
<pdfPageSize>612 x 792 pts (letter)</pdfPageSize>
<pdfWordsPerPage>834</pdfWordsPerPage>
<pdfText>true</pdfText>
</qualityIndicators>
<title>Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic</title>
<pmid><json:string>15709056</json:string>
</pmid>
<genre><json:string>other</json:string>
</genre>
<host><title>Journal of Antimicrobial Chemotherapy</title>
<language><json:string>unknown</json:string>
</language>
<issn><json:string>0305-7453</json:string>
</issn>
<eissn><json:string>1460-2091</json:string>
</eissn>
<publisherId><json:string>jac</json:string>
</publisherId>
<volume>55</volume>
<issue>suppl-1</issue>
<pages><first>i5</first>
<last>i21</last>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<namedEntities><unitex><date><json:string>1032</json:string>
<json:string>2554</json:string>
<json:string>1968</json:string>
<json:string>in the 20th century</json:string>
<json:string>2005</json:string>
<json:string>1957</json:string>
<json:string>1997</json:string>
<json:string>50s</json:string>
<json:string>1918</json:string>
<json:string>4000</json:string>
<json:string>the 20th century</json:string>
<json:string>2002</json:string>
<json:string>20th Century</json:string>
<json:string>1999</json:string>
<json:string>2003</json:string>
<json:string>1978</json:string>
<json:string>between December 2003 and January 2004</json:string>
<json:string>during the 20th century</json:string>
<json:string>2004</json:string>
<json:string>1996</json:string>
<json:string>3434</json:string>
</date>
<geogName></geogName>
<orgName><json:string>American Medical Association</json:string>
<json:string>Hoffmann-La Roche Ltd.</json:string>
<json:string>Hoffmann-La Roche Inc</json:string>
<json:string>University of Wales</json:string>
<json:string>European Commission</json:string>
<json:string>Netherlands, Thailand and Vietnam</json:string>
<json:string>Society for Antimicrobial Chemotherapy</json:string>
<json:string>Netherlands and Vietnam</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>Spontaneous</json:string>
<json:string>Hong Kong</json:string>
<json:string>P. M. Eds</json:string>
<json:string>Mutations</json:string>
<json:string>Regina Dutkowski</json:string>
<json:string>James Smith</json:string>
<json:string>Pia Suter</json:string>
<json:string>Evidence</json:string>
<json:string>Oseltamivir</json:string>
<json:string>Professor Noel</json:string>
<json:string>Journal</json:string>
<json:string>F. Hoffmann-La Roche</json:string>
</persName>
<placeName><json:string>Philadelphia</json:string>
<json:string>Switzerland</json:string>
<json:string>Vietnam</json:string>
<json:string>UK</json:string>
<json:string>Hong Kong</json:string>
<json:string>Cardiff</json:string>
<json:string>China</json:string>
<json:string>USA</json:string>
<json:string>Japan</json:string>
<json:string>Nutley</json:string>
<json:string>France</json:string>
<json:string>NJ</json:string>
<json:string>Netherlands</json:string>
<json:string>PA</json:string>
</placeName>
<ref_url><json:string>http://www.eiss.org</json:string>
</ref_url>
<ref_bibl><json:string>Stilianakis et al.</json:string>
<json:string>P. Ward et al.</json:string>
<json:string>Longini et al.</json:string>
<json:string>Kiso et al.</json:string>
<json:string>March 1918</json:string>
<json:string>Hien et al.</json:string>
<json:string>Welliver et al.</json:string>
<json:string>Hayden et al. (1999)</json:string>
<json:string>Peters et al. (2001)</json:string>
<json:string>June 2004</json:string>
<json:string>April 2003</json:string>
<json:string>Hayden et al. (2004)</json:string>
<json:string>Van Genugten et al.</json:string>
<json:string>Peters et al.</json:string>
<json:string>February 2001</json:string>
<json:string>Hayden et al.</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/HXZ-Z7QWKL7C-1</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - pharmacology & pharmacy</json:string>
<json:string>2 - microbiology</json:string>
<json:string>2 - infectious diseases</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - biomedical research</json:string>
<json:string>3 - microbiology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Infectious Diseases</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Pharmacology (medical)</json:string>
<json:string>1 - Life Sciences</json:string>
<json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string>
<json:string>3 - Pharmacology</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
<json:string>4 - pharmacologie. traitements medicamenteux</json:string>
</inist>
</categories>
<publicationDate>2005</publicationDate>
<copyrightDate>2005</copyrightDate>
<doi><json:string>10.1093/jac/dki018</json:string>
</doi>
<id>922F9D3E26EBD54DF6D00A45F3E4732514BE6241</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-Z7QWKL7C-1/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-Z7QWKL7C-1/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-Z7QWKL7C-1/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic</title>
<respStmt><resp>Références bibliographiques récupérées via GROBID</resp>
<name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name>
</respStmt>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Oxford University Press</publisher>
<availability><licence>JAC © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved</licence>
</availability>
<date when="2005-02">2005</date>
<date type="Copyright" when="2005">2005</date>
</publicationStmt>
<notesStmt><note type="content-type" source="other" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="other"><analytic><title level="a" type="main" xml:lang="en">Oseltamivir (Tamiflu<hi rend="superscript">®</hi>
) and its potential for use in the event of an influenza pandemic</title>
<author xml:id="author-0000"><persName><surname>Ward</surname>
<forename type="first">Penelope</forename>
</persName>
<affiliation><orgName type="">Roche Products Ltd</orgName>
<address><addrLine>Welwyn Garden City, Herts, UK F Hoffmann-La Roche, Basle, Switzerland F Hoffmann-La Roche Inc, Nutley, NJ, USA</addrLine>
<country key="US" xml:lang="en">UNITED STATES</country>
</address>
</affiliation>
<affiliation role="corresp">*Corresponding author. Tel: +44-1707-362843; Fax: +44-1707-365887; Email: penelope.ward@roche.com</affiliation>
</author>
<author xml:id="author-0001"><persName><surname>Small</surname>
<forename type="first">Ian</forename>
</persName>
<affiliation><orgName type="">Roche Products Ltd</orgName>
<address><addrLine>Welwyn Garden City, Herts, UK F Hoffmann-La Roche, Basle, Switzerland F Hoffmann-La Roche Inc, Nutley, NJ, USA</addrLine>
<country key="US" xml:lang="en">UNITED STATES</country>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><surname>Smith</surname>
<forename type="first">James</forename>
</persName>
<affiliation><orgName type="">Roche Products Ltd</orgName>
<address><addrLine>Welwyn Garden City, Herts, UK F Hoffmann-La Roche, Basle, Switzerland F Hoffmann-La Roche Inc, Nutley, NJ, USA</addrLine>
<country key="US" xml:lang="en">UNITED STATES</country>
</address>
</affiliation>
</author>
<author xml:id="author-0003"><persName><surname>Suter</surname>
<forename type="first">Pia</forename>
</persName>
<affiliation><orgName type="">Roche Products Ltd</orgName>
<address><addrLine>Welwyn Garden City, Herts, UK F Hoffmann-La Roche, Basle, Switzerland F Hoffmann-La Roche Inc, Nutley, NJ, USA</addrLine>
<country key="US" xml:lang="en">UNITED STATES</country>
</address>
</affiliation>
</author>
<author xml:id="author-0004"><persName><surname>Dutkowski</surname>
<forename type="first">Regina</forename>
</persName>
<affiliation><orgName type="">Roche Products Ltd</orgName>
<address><addrLine>Welwyn Garden City, Herts, UK F Hoffmann-La Roche, Basle, Switzerland F Hoffmann-La Roche Inc, Nutley, NJ, USA</addrLine>
<country key="US" xml:lang="en">UNITED STATES</country>
</address>
</affiliation>
</author>
<idno type="istex">922F9D3E26EBD54DF6D00A45F3E4732514BE6241</idno>
<idno type="ark">ark:/67375/HXZ-Z7QWKL7C-1</idno>
<idno type="other">dki018</idno>
<idno type="DOI">10.1093/jac/dki018</idno>
</analytic>
<monogr><title level="j" type="main">Journal of Antimicrobial Chemotherapy</title>
<title level="j" type="issue">Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic</title>
<title level="j" type="abbrev">J. Antimicrob. Chemother.</title>
<idno type="hwp">jac</idno>
<idno type="nlm-ta">J Antimicrob Chemother</idno>
<idno type="publisher-id">jac</idno>
<idno type="pISSN">0305-7453</idno>
<idno type="eISSN">1460-2091</idno>
<imprint><publisher>Oxford University Press</publisher>
<date when="2005-02">2005</date>
<biblScope unit="vol">55</biblScope>
<biblScope unit="issue">suppl_1</biblScope>
<biblScope unit="page" from="i5">i5</biblScope>
<biblScope unit="page" to="i21">i21</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-09"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
                        <ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><abstract xml:lang="en"><p>Recent cross species transmission of avian influenza has highlighted the threat of pandemic influenza. Oseltamivir (Tamiflu<hi rend="superscript">®</hi>
) has been shown to be effective in the treatment and prevention of epidemic influenza infection in adults, adolescents and children (≥ 1 year). Although oseltamivir has not been approved for prophylactic use in children, it has been shown to be effective. Oseltamivir is also active against avian influenza virus strains. Evidence suggests that lower doses or shorter durations of treatment/chemoprophylaxis other than those approved may not be effective and may contribute to emergence of viral resistance. Safety data from dose ranging studies show that 5 day courses of 150 mg twice daily for treatment and 6 week courses of 75 mg twice daily for prophylaxis were as well tolerated as the approved dose regimens. The use of oseltamivir in a pandemic is influenced by the goals of the pandemic plan developed by the responsible Government and Health Authority. To optimize use of antiviral medications, processes will be needed to collect, collate and report outcome data from treated patients and/or from use for chemoprophylaxis of pandemic influenza during the first-wave outbreaks. If oseltamivir is included in a national or regional pandemic plan, stockpiling of the material, either in the form of capsules or the bulk active pharmaceutical ingredient will be necessary. In the absence of a stockpile, there is no guarantee that an adequate supply of oseltamivir will be available.</p>
</abstract>
<textClass ana="subject"><keywords scheme="heading"><term>Supplement</term>
</keywords>
</textClass>
<textClass ana="keyword"><keywords scheme="KWD" xml:lang="en"><term>treatment</term>
<term>therapy</term>
<term>neuraminidase inhibitors</term>
</keywords>
</textClass>
<langUsage><language ident="en"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2019-12-09" who="#istex" xml:id="pub2tei">formatting</change>
<change xml:id="refBibs-istex" who="#ISTEX-API" when="2019-12-13">References added</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-Z7QWKL7C-1/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="US-ASCII"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType>
<istex:document><article xml:lang="en" article-type="other" dtd-version="2.3">

  <front>

    <journal-meta>

      <journal-id journal-id-type="hwp">jac</journal-id>

      <journal-id journal-id-type="nlm-ta">J Antimicrob Chemother</journal-id>

<journal-id journal-id-type="publisher-id">jac</journal-id>

      <journal-title>Journal of Antimicrobial Chemotherapy</journal-title>

      <abbrev-journal-title abbrev-type="publisher">J. Antimicrob. Chemother.</abbrev-journal-title>

      <issn pub-type="ppub">0305-7453</issn>

      <issn pub-type="epub">1460-2091</issn>

      <publisher>

        <publisher-name>Oxford University Press</publisher-name>

      </publisher>

    </journal-meta>

    <article-meta>

      <article-id pub-id-type="other">dki018</article-id>

      <article-id pub-id-type="doi">10.1093/jac/dki018</article-id>

      <article-categories>

        <subj-group subj-group-type="heading">

          <subject>Supplement</subject>

        </subj-group>

      </article-categories>

      <title-group>

        <article-title>Oseltamivir (Tamiflu<sup>®</sup>
) and its potential for use in the event of an influenza pandemic</article-title>

      </title-group>

      <contrib-group>

        <contrib contrib-type="author" xlink:type="simple">

          <name name-style="western">

            <surname>Ward</surname>

            <given-names>Penelope</given-names>

          </name>

          <xref rid="AFF1">1</xref>

          <xref rid="COR1">*</xref>

        </contrib>

        <contrib contrib-type="author" xlink:type="simple">

          <name name-style="western">

            <surname>Small</surname>

            <given-names>Ian</given-names>

          </name>

          <xref rid="AFF1">1</xref>

        </contrib>

        <contrib contrib-type="author" xlink:type="simple">

          <name name-style="western">

            <surname>Smith</surname>

            <given-names>James</given-names>

          </name>

          <xref rid="AFF2">2</xref>

        </contrib>

        <contrib contrib-type="author" xlink:type="simple">

          <name name-style="western">

            <surname>Suter</surname>

            <given-names>Pia</given-names>

          </name>

          <xref rid="AFF2">2</xref>

        </contrib>

        <contrib contrib-type="author" xlink:type="simple">

          <name name-style="western">

            <surname>Dutkowski</surname>

            <given-names>Regina</given-names>

          </name>

          <xref rid="AFF3">3</xref>

        </contrib>

        <aff><target target-type="aff" id="AFF1"></target>
<label>1</label>
Roche Products Ltd, Welwyn Garden City, Herts, UK; <target target-type="aff" id="AFF2"></target>
<label>2</label>
F. Hoffmann-La Roche, Basle, Switzerland; <target target-type="aff" id="AFF3"></target>
<label>3</label>
F. Hoffmann-La Roche Inc, Nutley, NJ, USA</aff>

      </contrib-group>

      <author-notes>

        <corresp id="COR1">*Corresponding author. Tel: +44-1707-362843; Fax: +44-1707-365887; Email: <ext-link xlink:href="penelope.ward@roche.com" ext-link-type="email" xlink:type="simple">penelope.ward@roche.com</ext-link>
</corresp>

      </author-notes>

      <pub-date pub-type="ppub">

        <month>2</month>

        <year>2005</year>

      </pub-date>

      <volume>55</volume>

      <issue>suppl_1</issue>

      <issue-title>Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic</issue-title>

      <fpage>i5</fpage>

      <lpage>i21</lpage>

      <permissions>

        <copyright-statement>JAC © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved</copyright-statement>

        <copyright-year>2005</copyright-year>

      </permissions>

      <self-uri content-type="arthw-pdf" xlink:href="dki018.pdf" xlink:type="simple"></self-uri>

      <abstract xml:lang="en">

        <p>Recent cross species transmission of avian influenza has highlighted the threat of pandemic influenza. Oseltamivir (Tamiflu<sup>®</sup>
) has been shown to be effective in the treatment and prevention of epidemic influenza infection in adults, adolescents and children (≥ 1 year). Although oseltamivir has not been approved for prophylactic use in children, it has been shown to be effective. Oseltamivir is also active against avian influenza virus strains. Evidence suggests that lower doses or shorter durations of treatment/chemoprophylaxis other than those approved may not be effective and may contribute to emergence of viral resistance. Safety data from dose ranging studies show that 5 day courses of 150 mg twice daily for treatment and 6 week courses of 75 mg twice daily for prophylaxis were as well tolerated as the approved dose regimens. The use of oseltamivir in a pandemic is influenced by the goals of the pandemic plan developed by the responsible Government and Health Authority. To optimize use of antiviral medications, processes will be needed to collect, collate and report outcome data from treated patients and/or from use for chemoprophylaxis of pandemic influenza during the first-wave outbreaks. If oseltamivir is included in a national or regional pandemic plan, stockpiling of the material, either in the form of capsules or the bulk active pharmaceutical ingredient will be necessary. In the absence of a stockpile, there is no guarantee that an adequate supply of oseltamivir will be available.</p>

      </abstract>

      <kwd-group kwd-group-type="KWD" xml:lang="en">

        <kwd>treatment</kwd>

        <kwd>therapy</kwd>

        <kwd>neuraminidase inhibitors</kwd>

      </kwd-group>

      <custom-meta-wrap>

        <custom-meta xlink:type="simple">

          <meta-name>hwp-legacy-fpage</meta-name>

          <meta-value>i5</meta-value>

        </custom-meta>

        <custom-meta xlink:type="simple">

          <meta-name>cover-date</meta-name>

          <meta-value>February 2005</meta-value>

        </custom-meta>

        <custom-meta xlink:type="simple">

          <meta-name>hwp-legacy-dochead</meta-name>

          <meta-value>Supplement</meta-value>

        </custom-meta>

      </custom-meta-wrap>

    </article-meta>

  </front>

</article>

</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic</title>
</titleInfo>
<titleInfo type="alternative" lang="en" contentType="CDATA"><title>Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic</title>
</titleInfo>
<name type="personal"><namePart type="given">Penelope</namePart>
<namePart type="family">Ward</namePart>
<affiliation>Roche Products Ltd, Welwyn Garden City, Herts, UK;</affiliation>
<affiliation>*Corresponding author. Tel: +44-1707-362843; Fax: +44-1707-365887; Email: penelope.ward@roche.com</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Ian</namePart>
<namePart type="family">Small</namePart>
<affiliation>Roche Products Ltd, Welwyn Garden City, Herts, UK;</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">James</namePart>
<namePart type="family">Smith</namePart>
<affiliation>F. Hoffmann-La Roche, Basle, Switzerland;</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Pia</namePart>
<namePart type="family">Suter</namePart>
<affiliation>F. Hoffmann-La Roche, Basle, Switzerland;</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Regina</namePart>
<namePart type="family">Dutkowski</namePart>
<affiliation>F. Hoffmann-La Roche Inc, Nutley, NJ, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="other" displayLabel="other" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</genre>
<originInfo><publisher>Oxford University Press</publisher>
<dateIssued encoding="w3cdtf">2005-02</dateIssued>
<copyrightDate encoding="w3cdtf">2005</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
</language>
<abstract lang="en">Recent cross species transmission of avian influenza has highlighted the threat of pandemic influenza. Oseltamivir (Tamiflu®) has been shown to be effective in the treatment and prevention of epidemic influenza infection in adults, adolescents and children (≥ 1 year). Although oseltamivir has not been approved for prophylactic use in children, it has been shown to be effective. Oseltamivir is also active against avian influenza virus strains. Evidence suggests that lower doses or shorter durations of treatment/chemoprophylaxis other than those approved may not be effective and may contribute to emergence of viral resistance. Safety data from dose ranging studies show that 5 day courses of 150 mg twice daily for treatment and 6 week courses of 75 mg twice daily for prophylaxis were as well tolerated as the approved dose regimens. The use of oseltamivir in a pandemic is influenced by the goals of the pandemic plan developed by the responsible Government and Health Authority. To optimize use of antiviral medications, processes will be needed to collect, collate and report outcome data from treated patients and/or from use for chemoprophylaxis of pandemic influenza during the first-wave outbreaks. If oseltamivir is included in a national or regional pandemic plan, stockpiling of the material, either in the form of capsules or the bulk active pharmaceutical ingredient will be necessary. In the absence of a stockpile, there is no guarantee that an adequate supply of oseltamivir will be available.</abstract>
<note type="author-notes">*Corresponding author. Tel: +44-1707-362843; Fax: +44-1707-365887; Email: penelope.ward@roche.com</note>
<subject lang="en"><genre>KWD</genre>
<topic>treatment</topic>
<topic>therapy</topic>
<topic>neuraminidase inhibitors</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Journal of Antimicrobial Chemotherapy</title>
</titleInfo>
<titleInfo type="abbreviated"><title>J. Antimicrob. Chemother.</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">0305-7453</identifier>
<identifier type="eISSN">1460-2091</identifier>
<identifier type="PublisherID">jac</identifier>
<identifier type="PublisherID-hwp">jac</identifier>
<identifier type="PublisherID-nlm-ta">J Antimicrob Chemother</identifier>
<part><date>2005</date>
<detail type="title"><title>Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic</title>
</detail>
<detail type="volume"><caption>vol.</caption>
<number>55</number>
</detail>
<detail type="issue"><number>suppl-1</number>
</detail>
<extent unit="pages"><start>i5</start>
<end>i21</end>
</extent>
</part>
</relatedItem>
<identifier type="istex">922F9D3E26EBD54DF6D00A45F3E4732514BE6241</identifier>
<identifier type="ark">ark:/67375/HXZ-Z7QWKL7C-1</identifier>
<identifier type="DOI">10.1093/jac/dki018</identifier>
<identifier type="href">dki018.pdf</identifier>
<identifier type="local">dki018</identifier>
<accessCondition type="use and reproduction" contentType="copyright">JAC © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource>
<recordOrigin>Converted from  (version 1.2.0) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2019-12-09</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-Z7QWKL7C-1/record.json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001421 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001421 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:922F9D3E26EBD54DF6D00A45F3E4732514BE6241
   |texte=   Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic

Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri